Wonder how many longs expected that we would still be
Wonder how many longs expected that we would still be waiting on P2b Prurisol top end results in the middle of July?
I am a novice to biotech investing and I originally thought by end of March was a given and resadjusted to Mid May when March went by in silence.
Now I don't try and peg any date but know we get news prior to 9/30.
For those that have been in plays like this before, what volume is necessary for us to feel that it is not just NR cycling funds thru IPIX as they seem to have been doing for years? Do most expect many 1MM+ volume days or should we expect even greater volume if we get strong P2b results or a strong partnership?
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...
Continue Reading
Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...
Continue Reading
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...
Continue Reading
Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...
Continue Reading
Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...
Continue Reading
A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...
Continue Reading
A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...
Continue Reading
Top 5 Most Recently Viewed Articles
Madison Tops Functional Employment Rankings Recently, Madison has been recognized as the leading metro area in the country for functional employment, a title derived from a comprehensive analysis by the Ludwig Institute for Shared Economic Prosperity (LISEP). This achievement highlights Madison’s robust job growth, higher wage levels, and an overall favorable work...
Continue Reading
Class Action Lawsuits Overview In recent developments, Bragar Eagel & Squire, P.C., a well-known shareholder rights law firm, has informed investors about multiple class action lawsuits filed against notable companies such as WEBTOON Entertainment, Inc. (NASDAQ: WBTN), Elanco Animal Health Incorporated (NYSE: ELAN), and Domino's Pizza, Inc. (NYSE: DPZ). Shareholders in...
Continue Reading
The Shift to a Multipolar World: What Investors Need to Know The global landscape has transformed, moving away from a system dominated by one major power to a multipolar world. This significant shift means that traditional geopolitical assumptions guiding investors are no longer reliable. Marko Papic, Chief Strategist at BCA Research, recently underscored this point in a...
Continue Reading
Market Dynamics and Broadcom's Recent Performance As the Nasdaq 100 index faces a notable correction, Broadcom Inc. (NASDAQ: AVGO) has managed to stand out with a remarkable surge of 12.82% during after-hours trading. However, renowned market analyst Jim Cramer expresses skepticism regarding its ability to reverse the overall market decline. Understanding the Market...
Continue Reading
NSFOCUS Achieves Notable Recognition in Cybersecurity In a significant development, NSFOCUS has earned recognition as a 'Stars Company' in the DDoS Protection and Mitigation Security sector by the esteemed MarketsandMarkets' 360Quadrants platform. This accolade reflects NSFOCUS's unwavering commitment to innovation and excellence in delivering cutting-edge solutions for...
Continue Reading